Walter Winshall

Walter Winshall is the Founder and Managing Partner of Collaborative Seed & Growth Partners, a Boston-based venture capital firm. The firm primarily focuses on early-stage investments, with a strong emphasis on the life sciences, particularly biotech, therapeutics, and digital health, as well as deep technology sectors. Winshall's extensive background and association with institutions like MIT underscore the firm's commitment to backing scientifically rigorous and highly innovative companies.

Collaborative Seed & Growth Partners boasts a notable track record of identifying and nurturing high-potential ventures. Their portfolio includes several companies that have achieved significant milestones, demonstrating the firm's strategic acumen. For instance, Akili Interactive, a pioneering digital therapeutics company, successfully went public via a SPAC, and Evelo Biosciences, a microbiome company, also achieved a successful IPO. A particularly significant exit was the acquisition of Nimbus Therapeutics by Takeda, a deal valued at up to $6 billion, highlighting the firm's capacity to support companies through to substantial liquidity events.

The firm typically invests in companies at the seed and early growth stages, providing crucial capital for initial development and subsequent scaling. While specific check sizes are not publicly disclosed, their participation in multi-million dollar seed and Series A rounds suggests initial investments ranging from approximately $250,000 to $2,000,000. This range enables them to support nascent companies through critical early phases, often acting as a key early investor. Their investment strategy is centered on identifying and empowering disruptive solutions with the potential for significant market impact.